Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin

Journal of Applied Microbiology

Volumn 117, Issue 5, 2014, Pages 1253-1259

  Quintana, V M ^a   Torres, N I ^a,d   Wachsman, M B ^a   Sinko, P J ^b   Castilla, V ^a   Chikindas, M ^c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

Antimicrobial peptide; Antiviral activity; Bacteriocin; Herpes simplex virus; Microbicide; Subtilosin

Indexed keywords

BACTERIOLOGY; CELL CULTURE; ENZYME ACTIVITY; GLYCOPROTEINS; PEPTIDES;

ANTIMICROBIAL PEPTIDE; ANTIVIRAL ACTIVITIES; ANTIVIRALS; BACILLUS AMYLOLIQUEFACIENS; BACTERIOCINS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS TYPE-2; MICROBICIDES; MODE OF ACTION; SUBTILOSIN;

VIRUSES;

ANTIVIRUS AGENT; BACTERIOCIN; GLYCOPROTEIN; GLYCOPROTEIN GD; POLYPEPTIDE ANTIBIOTIC AGENT; SUBTILOSIN; UNCLASSIFIED DRUG; CYCLOPEPTIDE; SBOA PROTEIN, BACILLUS SUBTILIS;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BACILLUS AMYLOLIQUEFACIENS; CELL CULTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; HERPES SIMPLEX VIRUS 2; IMMUNOFLUORESCENCE TEST; INTRACELLULAR SPACE; INTRACELLULAR TRANSPORT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN ISOLATION; VERO CELL LINE; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; HUMAN;

SIMPLEXVIRUS;

ANIMALS; ANTIVIRAL AGENTS; BACTERIOCINS; CERCOPITHECUS AETHIOPS; HERPESVIRUS 2, HUMAN; HUMANS; PEPTIDES, CYCLIC; VERO CELLS;

EID: 84907990431     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/jam.12618     Document Type: Article

References (29)

1. Babasaki, K., Takao, T., Shimonishi, Y. and Kurahashi, K. (1985) Subtilosin A, a new antibiotic peptide produced by Bacillus subtilis: isolation, structural analysis, and biogenesis. J Biochem 98, 585-603.
2. Belshe, R.B., Leone, P.A., Bernstein, D.I., Wald, A., Levin, M.J., Stapleton, J.T., Gorfinkel, I., Morrow, R.L. et al. (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366, 34-43.
3. Chentoufi, A.A. and Benmohamed, L. (2012) Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections. Clin Dev Immunol 2012, 149135.
4. Chilukuri, S. and Rosen, T. (2003) Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 21, 311-320.
5. Choong, K., Walker, N., Apel, A. and Whitby, M. (2010) Aciclovir-resistant herpes keratitis. Clin Experiment Ophtalmol 38, 309-313.
6. Denizot, F. and Lang, R. (1986) Rapid colorimetric assay for cell growth and survival. J Immunol Methods 89, 271-277.
7. Des Jarlais, D.C., Arasteh, K., McKnight, C., Perlman, D.C., Feelemyer, J., Hagan, H. and Cooper, H.L. (2014) HSV-2 Co-infection as a driver of HIV transmission among heterosexual non-injecting drug users in New York City. PLoS ONE 9, e87993.
8. Efstathiou, S. and Preston, C.M. (2005) Towards an understanding of the molecular basis of herpes simplex virus latency. Virus Res 111, 108-119.
9. Férir, G., Petrova, M.I., Andrei, G., Huskens, D., Hoorelbeke, B., Snoeck, R., Vanderleyden, J., Balzarini, J. et al. (2013) The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications. PLoS ONE 8, e64010.
10. Fife, K.H., Warren, T.J., Justus, S.E. and Heitman, C.K. (2008) An international, randomized, double-blind, placebo controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. Sex Transm Dis 35, 666-673.
11. Freeman, E.E., Weiss, H.A., Glynn, J.R., Cross, P.L., Whitworth, J.A. and Hayes, R.J. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20, 73-83.
12. Gottlieb, S.L., Low, N., Newman, L.M., Bolan, G., Kamb, M. and Broutet, N. (2014) Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine 32, 1527-1535.
13. Johnston, C., Saracino, M., Kuntz, S., Magaret, A., Selke, S., Huang, M.L., Schiffer, J.T., Koelle, D.M. et al. (2012) Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 379, 641-647.
14. van Kuijk, S., Noll, K.S. and Chikindas, M.L. (2012) The species-specific mode of action of the antimicrobial peptide subtilosin against Listeria monocytogenes Scott A. Lett Appl Microbiol 54, 52-58.
15. Marx, R., Stein, T., Entian, K.D. and Glaser, S.J. (2001) Structure of the Bacillus subtillis peptide antibiotic subtilosin A determined by 1H NMR and matrix assisted laser desorption/ionization time-of-flight mass spectrometry. J Protein Chem 20, 501-506.
16. Noll, K.S., Prichard, M.N., Khaykin, A., Sinko, P.J. and Chikindas, M.L. (2012) The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate, and ε-poly-L-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli. Antimicrob Agents Chemother 56, 1756-1761.
17. Saeed, S., Rasool, S.A., Ahmad, S., Zaidi, S.Z. and Rehmani, S. (2007) Antiviral activity of staphylococcin 188: a purified bacteriocin like inhibitory substance isolated from Staphylococcus aureus AB188. Res J Microbiol 2, 796-806.
18. Serkedjieva, J., Danova, S. and Ivanova, I. (2000) Antiinfluenza virus activity of a bacteriocin produced by Lactobacillus delbrueckii. Appl Biochem Biotechnol 88, 285-298.
19. Sutyak, K.E., Anderson, R.A., Dover, S.E., Feathergill, K.A., Aroutcheva, A.A., Faro, S. and Chikindas, M.L. (2008a) Spermicidal activity of the safe natural antimicrobial peptide subtilosin. Infect Dis Obstet Gynecol 2008, 540758.
20. Sutyak, K.E., Wirawan, R.E., Aroutcheva, A.A. and Chikindas, M.L. (2008b) Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens. J Appl Microbiol 104, 1067-1074.
21. Thurman, A.R. and Doncel, G.F. (2012) Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention. Int J STD AIDS 23, 613-619.
22. Todorov, S.D., Wachsman, M.B., Knoetze, H., Meincken, M. and Dicks, L.M. (2005) An antibacterial and antiviral peptide produced by Enterococcus mundtii ST4V isolated from soya beans. Int J Antimicrob Agents 25, 508-513.
23. Todorov, S.D., Wachsman, M., Tomé, E., Dousset, X., Destro, M.T., Dicks, L.M., Franco, B.D., Vaz-Velho, M. et al. (2010) Characterisation of an antiviral pediocin-like bacteriocin produced by Enterococcus faecium. Food Microbiol 27, 869-879.
24. Torres, N.I., Noll, K.S., Xu, S., Li, J., Huang, Q., Sinko, P.J., Wachsman, M.B. and Chikindas, M.L. (2013) Safety, formulation, and in vitro antiviral activity of the antimicrobial peptide subtilosin against herpes simplex virus type 1. Probiotics Antimicrob Proteins 5, 26-35.
25. Turovskiy, Y., Cheryian, T., Algburi, A., Wirawan, R.E., Takhistov, P., Sinko, P.J. and Chikindas, M.L. (2012) Susceptibility of Gardnerella vaginalis biofilms to natural antimicrobials subtilosin, ε-poly-L-lysine, and lauramide arginine ethyl ester. Infect Dis Obstet Gynecol 2012, 284762.
26. van Velzen, M., van Loenen, F.B., Meesters, R.J., de Graaf, M., Remeijer, L., Luider, T.M., Osterhaus, A.D. and Verjans, G.M. (2012) Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 205, 1539-1543.
27. Wachsman, M.B., Farías, M.E., Takeda, E., Sesma, F., de Ruiz Holgado, A.P., de Torres, R.A. and Coto, C.E. (1999) Antiviral activity of enterocin CRL35 against herpesviruses. Int J Antimicrob Agents 12, 293-299.
28. Wachsman, M.B., Castilla, V., de Ruiz Holgado, A.P., de Torres, R.A., Sesma, F. and Coto, C.E. (2003) Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro. Antiviral Res 58, 17-24.
29. Wald, A., Corey, L., Timmler, B., Magaret, A., Warren, T., Tyring, S., Johnston, C., Kriesel, J. et al. (2014) Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med 370, 201-210.